Stanford AI Identifies a Natural Peptide That May Reduce Appetite

Stanford Medicine researchers used artificial intelligence to identify a naturally occurring molecule that may suppress appetite and promote fat loss. The peptide has shown promising results in animal studies, though it has not yet been tested in human clinical trials.

Called BRP (BRINP2-related peptide), the molecule is a compact peptide made up of 12 amino acids that the human body produces. Researchers used an AI tool called Peptide Predictor to screen human protein-coding genes for peptide fragments that could help regulate appetite.

In studies involving mice and pigs, BRP:

• Reduced food intake by up to 50%.
• Promoted fat-specific weight loss.
• Did not cause nausea, constipation, or significant muscle loss in the animals studied.

Unlike semaglutide—the active ingredient in Ozempic and Wegovy—which acts on receptors throughout the gut, pancreas, and brain, BRP appears to target the hypothalamus, the brain’s hunger-control center. This may offer a more focused route to appetite regulation.

The research was led by Dr. Katrin Svensson, an assistant professor of pathology. Svensson has co-founded a company that plans to begin human clinical trials in the future.

Important: BRP is still an experimental molecule, and its effects have only been studied in animals so far. Further research, including human trials, is needed to determine whether it is safe and effective for people.

The discovery highlights the potential for AI to help accelerate research into metabolic health and new treatments.

Source: ScienceDaily – AI Helps Stanford Scientists Discover a “Natural Ozempic” (November 4, 2026)